Site içinde arama yapın

bir ses eklendi Health

2026-01-23 09:09:12 -

Primary Sclerosing Cholangitis Market: Is 2026 the Year We Finally Outsmart This "Uncurable" Liver Disease?

As of January 23, 2026, the primary sclerosing cholangitis market is identifying as one of the most critical unmet needs in hepatology, with its 2026 valuation reaching approximately $175 million to $180 million. The 2026 landscape is defined by a promising CAGR of 4.9% to 8.6%, driven by an unprecedented surge in orphan drug designations and late-stage clinical breakthroughs. This 2026...

0 Yorumlar 0 hisse senetleri 561 Views 0 önizleme